COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04362176


Column Value
Trial registration number NCT04362176
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : Nov. 5, 2021, 2 p.m.
Source : ClinicalTrials.gov

Todd Rice, MD

Contact
Last imported at : Nov. 5, 2021, 2 p.m.
Source : ClinicalTrials.gov

todd.rice@vumc.org

Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2020-04-24

Recruitment status
Last imported at : Nov. 5, 2021, 2 p.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

multi-center

Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov

inclusion criteria: age greater than or equal to 18 years currently hospitalized or in an emergency department with anticipated hospitalization symptoms of acute respiratory infection, defined as one or more of the following: cough chills, or a fever (greater than 37.5° c or 99.5° f) shortness of breath, operationalized as a patient having any of the following: i. subjective shortness of breath reported by a patient or surrogate. ii. tachypnea with respiratory rate of greater than 22 breaths per minute iii. hypoxemia, defined as spo2 less than 92% on room air, new receipt of supplemental oxygen to maintain spo2 greater than or equal to 92%, or increased supplemental oxygen to maintain spo2 greater than or equal to 92% for a patient on chronic oxygen therapy laboratory-confirmed sars-cov-2 infection within the past 14 days

Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov

prisoner unable to randomize within 14 days after onset of acute respiratory infection symptoms patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) inability to be contacted on day 29-36 for clinical outcome assessment receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days contraindications to transfusion or history of prior reactions to transfused blood products plan for hospital discharge within 24 hours of enrollment previous enrollment in this trial previous laboratory-confirmed sars-cov-2 infection before the current illness enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy prior receipt of sars-cov-2 vaccine

Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Vanderbilt University Medical Center

Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

United States

Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

No restriction on type of patients

Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

0: No restriction on type of patients

Total sample size
Last imported at : Nov. 5, 2021, 2 p.m.
Source : ClinicalTrials.gov

974

primary outcome
Last imported at : Nov. 4, 2022, 8 a.m.
Source : ClinicalTrials.gov

COVID-19 7-point Ordinal Clinical Progression Outcomes Scale Score

Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov

Phase 3

Arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]